Publications des scientifiques de l'IRD

Tahar Rachida, Almelli T., Debue C., Ngane V. F., Allico J. D., Youdom S. W., Basco Leonardo. (2014). Randomized trial of artesunate-amodiaquine, atovaquone-proguanil, and artesunate-atovaquone-proguanil for the treatment of uncomplicated falciparum malaria in children. Journal of Infectious Diseases, 210 (12), p. 1962-1971. ISSN 0022-1899.

Titre du document
Randomized trial of artesunate-amodiaquine, atovaquone-proguanil, and artesunate-atovaquone-proguanil for the treatment of uncomplicated falciparum malaria in children
Année de publication
2014
Type de document
Article référencé dans le Web of Science WOS:000345771200015
Auteurs
Tahar Rachida, Almelli T., Debue C., Ngane V. F., Allico J. D., Youdom S. W., Basco Leonardo
Source
Journal of Infectious Diseases, 2014, 210 (12), p. 1962-1971 ISSN 0022-1899
Artemisinin-based combination therapies (ACTs) are recommended for the treatment of acute uncomplicated falciparum malaria in many malaria-endemic countries. Despite the emergence of artemisinin resistance, few alternative non-ACTs, including atovaquone-proguanil, are currently available. Plasmodium falciparum-infected Cameroonian children a parts per thousand currency sign5 years old (n = 338) were randomly assigned to artesunate-amodiaquine, atovaquone-proguanil, or artesunate-atovaquone-proguanil treatment groups and followed for 28 days, according to the standard World Health Organization protocol. In vitro response to atovaquone and cytochrome b sequence of clinical isolates were determined. Eight late failures and 16 failures (8 late and 8 early failures) were observed after artesunate-amodiaquine and atovaquone-proguanil therapies, respectively. Most late failures were due to reinfections. Artesunate-atovaquone-proguanil was not associated with any failure. After correction by genotyping, per-protocol analysis showed no difference in the efficacy of 3 drugs. However, the proportion of atovaquone-proguanil-treated patients with positive smears on day 3 was much higher (36.0%; P < .05) than that of the artesunate-amodiaquine (2.9%) and artesunate-atovaquone-proguanil (1.0%) groups. In vitro response and cytochrome b sequence did not indicate atovaquone resistance. Atovaquone-proguanil was characterized by a slow blood schizontocidal action and resulted in early treatment failure in a few patients. Artesunate-atovaquone-proguanil was a highly effective alternative treatment. UMIN000003813.
Plan de classement
Santé : généralités [050] ; Entomologie médicale / Parasitologie / Virologie [052] ; Sciences du monde végétal [076]
Description Géographique
CAMEROUN
Localisation
Fonds IRD [F B010063089]
Identifiant IRD
fdi:010063089
Contact